Background: Anti-TNF therapy in IBD patients during pregnancy has been linked to lower birth weight, shorter gestational term and in some studies also with more frequent birth defects and spontaneous abortions. Recent results indicate that disease severity and activity, rather than anti-TNF therapy per se, are the main determinants of pregnancy outcome, however, negative effect of anti-TNF cannot be ruled out. In case of original infliximab (IFX), it is considered that benefit of treatment outweighs the potential harm, but it remains an open question in case of biosimilar IFX.
Disease activity at conception and birth weight Caesarean section was performed in 70% (14) cases, 79% (11) of which had history of perianal disease. No perinatal complications and birth defects were reported besides a single case of cleft palate. Last IFX administration occurred 12.1 ± 6.6 weeks before delivery. Mean IFX cord blood levels in anti-IFX negative subjects were 11.2 ± 15.0 μg/ml and were negatively correlated with time remaining to delivery since administration of last dose (r S = −0.6759; p = 0.0069).
Infliximab cord blood levels.
Conclusions: This is, to our knowledge, the first report of pregnancy outcomes in women exposed to biosimilar IFX. Under constrains given by limited sample size, no new safety concerns have so far arisen. Background: Vedolizumab is α4β7 integrin antagonist licenced to treat moderate to severely active Crohn's disease (CD) as well as ulcerative colitis. The aim of this study was to examine the efficacy of vedolizumab in patients with CD at a single tertiary IBD centre in the UK, and whether efficacy varies depending on disease location in this heterogeneous condition. Methods: Clinical records of patients with CD commenced on vedolizumab between 11/05/2015 and 01/12/2016 were examined retrospectively. Clinicopathological features and disease activity using Harvey Bradshaw Activity Index (HBAI) were collected at baseline, and at Weeks 14, 30 and at Week 52. Response to vedolizumab was defined as reduction in HBAI score ≤3 compared with baseline, and remission was defined as HBAI score ≤4 at these time points. For patients with a stoma, response was defined as a reduction in CRP ≥ 20% or radiological improvement, and remission was defined as normalisation of CRP ≤ 10 mg/l or radiological resolution of disease activity. Results: Forty patients with CD were commenced on vedolizumab during the study period. Out of the 40 patients, 8 were excluded from the data analysis due to incomplete data. Eighteen patients (57%) had ileocolonic disease, 11 patients (34%) had colonic disease, and 3 patients (9%) had small-bowel disease. Mean age at the time of first Vedolizumab infusion was 29.3. Mean age at diagnosis was 18.1 with mean time between diagnosis and first vedolizumab infusion of 10.1 years. Twenty-one patients (66%) were taking immunomodulator (IM) and only 1 patient was anti-TNF naïve (3%) at the time of the first vedolizumab infusion. Sixteen patients Out of 18 patients who continued vedolizumab for 1 year, 10 (56%) were in remission. Out of these 10 patients, 4 had colonic disease and 6 had ileocolonic disease. The three patients with small-bowel disease were all non-responders. The rate of remission at 1 year was lower in the patients with concomitant use of IM (n = 5/21, 24%) compared with IM (n = 5 of 11, 45%). Six patients underwent surgery within 1 year of receiving their first vedolizumab infusion. Conclusions: CD patients treated with vedolizumab achieved remission in 44% at Week 14, in 44% at 30 weeks and in 31% at Week 52. Vedolizumab was most effective at maintaining remission at 52 weeks in patients with colonic disease (n = 4 of 9, 44%) compared with patients with ileocolic disease (n = 6 of 20, 30%) and patients with small-bowel disease (n = 0 of 3, 0%). Background: Iron deficiency anaemia is a common extraintestinal manifestation of inflammatory bowel disease and is usually diagnosed by multiple parameters. Choice of a single iron biomarker for IDA screening remains controversial. 1 The most commonly used parameter, ferritin, is an acute-phase protein and may therefore be strongly influenced by inflammatory activity. Zinc protoporphyrin (ZPP) to haem ratio has proved a sensitive and specific marker for functional iron deficiency. We evaluated the diagnostic performance of ZPP in ID, IDA, anaemia of chronic disease (ACD) and combined ACD/IDA in patients with IBD. Methods: Data including blood count, transferrin saturation (TSAT), serum ferritin, CRP, and ZPP were analysed from 101 adults with IBD (62 CD; 40 UC; mean age 36.4 ± 13.1 years, 44% male) who consecutively attended our centre for routine evaluation between 05/2008 and 12/2013. Correlation between iron biomarkers und inflammation was measured by Spearman correlation. Anaemia was defined in accordance with WHO criteria (Hb <13 g/ dl males/<12 g/dl females). In the modified multiple-criteria model, 1 ID was considered present if ≥2 values from ferritin (<30 µg/l), TSAT (< 20%), and ZPP (>40 µmol/mol Hb) were abnormal. Anaemia was classified as IDA if CRP ≤5 mg/l and TSAT<20% and ferritin < 30 µg/l; as ACD if active inflammation (CRP >5 mg/l) was present and TSAT < 20% and ferritin ≥100 µg/l; and as mixed anaemia, IDA/ ACD, if active inflammation (CRP >5 mg/l) was present and TSAT <20% and ferritin <100 µg/l. 
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Results:
The prevalence of IDA and ACD was 17% (n = 17) and 3% (n = 3), respectively, while mixed anaemia (IDA/ACD) was identified in 23% (n = 23). Absolute ID without anaemia was found in 48 patients (47%). ZPP correlated better with Hb values than ferritin (correlation coefficients: 0.672 and 0.409, respectively, for ZPP and ferritin, p < 0.01). No correlation was found between ZPP und CRP (−0.05, p >0.5), while the acute-phase protein ferritin was found to correlate with CRP (correlation coefficient: 0.329, p < 0.01). Receiver operating characteristics (ROC) curves indicated that ZPP has high sensitivity and specificity for the determination of absolute ID and IDA (AUC: 0.77 and 0.75, respectively). Conclusions: ZPP is a reliable marker of iron-deficient erythropoiesis. Unlike ferritin, ZPP is not influenced by chronic inflammation. We propose that ZPP has utility not only in IBD, but also in patients with other chronic inflammatory conditions.
